Why Mechanistic Biology Still Matters (Part 4 of 4)

This is the final post in a series reflecting on themes from FOG (Boston) and EACR (Budapest).

Click to read Part One, Part Two and Part Three.

I’ve saved this topic for last because it’s less of an observation and more of a personal perspective, one I’d happily discuss over a coffee.

Across both conferences, the direction was clear: researchers want more data types from more compartments, using less of their precious samples. Multiomics integration is the expectation. The technology to deliver on that expectation is maturing rapidly.

But sitting through multiple sessions on multiomic workflows, I kept thinking about a distinction that didn’t always get enough airtime: describing a system in ever-greater molecular detail is not the same as understanding it.

The papers that ultimately change clinical practice tend not to be the ones that profiled fifteen layers and presented a correlation heatmap. They’re the ones that identified a specific mechanism, validated it rigorously, and translated that understanding into something actionable, whether that’s a diagnostic marker, a therapeutic target, or a clinical decision.

Multiomic profiling is enormously valuable as a discovery tool. It’s how you find the signal. But the signal still needs to be followed up with focused, mechanistic work that tests whether the correlation is real, whether it’s causal, and whether it holds up across patient populations and experimental conditions.

I think the field sometimes risks conflating the ability to measure more with the ability to understand more. The distinction matters most when the goal is clinical translation.

This tension showed up concretely in the spatial proteomics landscape. As I discussed in Part 2, the field is bifurcating into high-plex discovery panels and low-plex clinical deployment panels. That bifurcation is essentially the field recognising this point: discovery needs breadth, but clinical translation needs depth.

Once you’ve used a hundred-marker panel to identify the seven targets that matter in a given tumour microenvironment, what pharma actually wants is a small, validated, reproducible panel that reads out those seven targets reliably across multiple clinical samples and sites. The value shifts from “how many markers can we measure” to “how well do we understand the ones that matter.”

That transition from discovery to deployment is where mechanistic understanding becomes essential. You can’t validate a clinical panel without understanding why those markers matter, how they interact, and what confounders might affect interpretation in a real-world clinical setting.

In this series we covered multiomic convergence, spatial maturation, AI integration, the shift to human-relevant models, and now the case for mechanistic depth over breadth. These themes aren’t independent. They’re all aspects of a field that’s becoming more integrated, more translational, and more demanding in terms of rigour and reproducibility. 

The decisions being made now about standards, validation, and infrastructure will determine how quickly these technologies reach routine clinical use. As I mentioned in Part 1, the scientists who shaped this field thought in decades. The challenges ahead deserve the same approach. 

At Millennium Science, we attend conferences like FOG and EACR to understand where the field is heading, so we can make sure ANZ researchers have access to the tools and technologies that support their best work. If any of these themes resonate with your own research, we’d genuinely welcome the conversation.